Infinity Gears Up For Duvelisib Filing, But Differentiation Still A Challenge
Executive Summary
Duvelisib is on track for parallel filings for CLL and iNHL in 2016, but the company still has work to do in differentiating the PI3 kinase inhibitor, which it says could come through additional studies beyond pivotal trials.